• New Approaches to Treating Osteoporosis
     

    New Approaches to Treating Osteoporosis

    Speaker: Michael McClung, MD. Michael McClung, MD, gives us an update on new and expected drug therapies that are nearing the end of their clinical development. Dr. McClung also reviews current agents on the market for osteoporosis treatment. New Approaches to Treating Osteoporosis PDF Recorded at Northern California Institute for […]

    Read full article

  • Bone and Inflammation
     

    Bone and Inflammation

    Speaker: Robin Dore, M.D. Inflammation is a common pathophysiologic pathway for many disease states. It has become apparent that inflammation is an important risk factor for bone loss and fracture. This lecture reviews that relationship. Recorded at Northern California Institute for Bone Health, Osteoporosis Update 2015, on June 19, 2015, […]

    Read full article

  • Chronic Kidney Disease and Osteoporosis
     

    Chronic Kidney Disease and Osteoporosis

    The prevalence of both osteoporosis and chronic kidney disease increase with aging. The frequency with which they both occur in the same individual is high. How to differentiate osteoporosis from chronic kidney disease-mineral and how to treat each bone disorder is the subject of much debate. Dr. Miller, an international […]

    Read full article

  • What is Osteoporosis?
     

    What is Osteoporosis?

    An estimated 150 million people worldwide have osteoporosis leaving them at risk for the first-time. Due to its prevalence worldwide, osteoporosis is considered as a serious public health concern. Currently it is estimated that over 200 million people worldwide suffer from this disease1. Approximately 30% of all postmenopausal women have […]

    Read full article

  • Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
     

    Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.

    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. INTRODUCTION: The prevalence of both osteoporosis and renal impairment increases with age. METHODS: Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.

    Read full article